Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. - Wikidata - awgldk - TriplyDB

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

http://www.wikidata.org/entity/Q43873032

about

PI3K/AKT/mTOR Pathway in Angiogenesis Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case report Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae.Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals Potential use of rapamycin in HIV infection Updates of mTOR inhibitors Cholesterol trafficking is required for mTOR activation in endothelial cells Rapamycin and mTOR kinase inhibitors CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management Persistent androgen receptor addiction in castration-resistant prostate cancer Neoplastic disease after liver transplantation: Focus on de novo neoplasms Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment Targeting the intragraft microenvironment and the development of chronic allograft rejection The search for antiaging interventions: from elixirs to fasting regimens Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab Management of recurrent hepatocellular carcinoma after liver transplant Broad targeting of angiogenesis for cancer prevention and therapy Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis An overview of clinical and experimental treatment modalities for port wine stains Endothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult.Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Cell and Signal Components of the Microenvironment of Bone Metastasis Are Affected by Hypoxia The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses mTOR and cancer therapy Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome PI3K at the crossroads of tumor angiogenesis signaling pathways Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET

P2860

Q21129332-95AAB9F4-9D1D-492A-BFC6-90F4442ABB0A Q21261410-162E8B4B-58DF-44E4-B107-DB6A347414ED Q24519078-A2CC1D55-1635-4B4A-820E-CA7912E5BC66 Q24537557-C8450BA7-D62F-4E40-9DF9-C3198A953C50 Q24563431-19E7AF12-3DB2-44E2-AD94-FBB46B7974F9 Q24606795-A4CA1280-3391-4BEA-AA3D-E907AC4A1814 Q24607170-49335996-1842-467F-9831-BB3DF7679CD5 Q24620236-F51C3BAF-5F0F-40CB-A3A2-30322CDE6930 Q24644623-6A4DC885-F38D-419E-8C4F-2C51264FDFA6 Q24672058-59319D1D-8954-42A7-BF77-24F4098FF42C Q24806542-EAAD6625-5511-4148-8C6C-EE5011908009 Q26749011-538E284C-731C-44F6-82C1-A64ACD668AF4 Q26766049-D1BE3781-BB1F-4420-95E6-704C3FADDF36 Q26772295-44FDE82B-0AD0-475C-A029-933E1E8C426B Q26777163-4941938E-DE18-4F37-9A62-CFBCC4AD769B Q26798306-482AF8DB-E2C3-4342-AD4B-51E140F653F6 Q26851417-A720E7DC-8DCD-47CD-9BDB-4107D6C521E7 Q26851436-EDDD6D44-7FF4-4D39-ABDE-9C20D20BB4EE Q26852299-FC3DC593-D6F1-4B7E-9DF2-AE77B7E207EF Q26852762-4BE807A9-829F-4930-B554-E831C8ACC326 Q26863497-833134EE-C08D-47F4-B73A-4768339A1EF3 Q26864200-CC90C28D-1391-4E02-833D-F6EF8EE8C15C Q26997063-00CA837A-F111-43DB-8310-59C1E4366357 Q27002903-711CA59D-9061-4E90-B893-EB10F35D8069 Q27025406-F953E6CE-6FB4-486C-BBB6-A1D72B740EC4 Q27026170-B5D086CC-FF5A-47FB-9587-39C13EA61E07 Q27304564-C2BF0C97-554B-4F5F-986D-19D1826DB95A Q27652488-548623ED-D18F-4098-89E7-2A99B6F42745 Q27824855-2EEEAFAF-4AD6-42FC-86EB-7CC8A58633D4 Q27852608-A7C49CC7-A5B3-4F28-BED3-D510E2730FA0 Q28067598-0BA270C2-E506-470D-AEBF-25BA7C4BFE82 Q28071388-D8B811B7-97AB-4266-AACA-40D7E6EC2B8C Q28072232-1E045F35-D09B-4D16-96F7-F1F48DE76389 Q28240102-0B9EA67C-27E8-4277-AF45-896C516A161C Q28268516-6A0F328B-E856-4CBE-A3DB-E233BD9E2BBA Q28305337-8BCB1805-F2D0-48CD-A770-ED04FA084AA5 Q28305597-6B794349-B99B-4DDB-8151-84FCB5CC4D5E Q28396795-0E771DBC-A4E2-4569-888B-950A469D6904 Q28486318-883CF15D-D1F3-4E8B-9891-5EA582CE0DE8 Q28487987-AC7A4717-E311-4360-BD09-66D7EAE7C189

P2860

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

http://www.wikidata.org/entity/Q43873032

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@en

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@nl

type

label

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@en

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@nl

prefLabel

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@en

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@nl

P1433

Q43873032-58C39A76-BEE0-448D-81F1-B0FC5D5F0AE9

P1476

Q43873032-7C0F40FD-5757-447B-BB90-92552831052A

P2093

Q43873032-13EA8075-710D-448E-A260-B18CF37A4645

Q43873032-23186565-4902-4803-9F56-ABA0B31809FE

Q43873032-2898A8F8-C5DD-4754-8CDA-FEB0B2597316

Q43873032-40E97D40-F731-4A90-BC2C-C0EA0D6ECE0B

Q43873032-43200936-87D0-478A-8900-FD4E03AF47B7

Q43873032-55C268B5-CDB4-422E-8DD7-A9C58C9CFD66

Q43873032-7648E43C-C809-4FBF-9D1F-EEA546B6016D

Q43873032-78AAFE39-318A-432F-A29E-16555033F80B

Q43873032-811C0A60-38B6-417F-BFC3-CBC46A51A119

Q43873032-E8377A86-5711-4B4A-9AF5-05283F60EA96

P2888

Q43873032-C84BDA4C-9171-4468-A652-9BF552696FFA

P304

Q43873032-C6D423F7-1510-4C3B-AA63-840B3B4D7765

P31

Q43873032-FF83368B-34F6-416B-8017-221C5BD69410

P356

Q43873032-212F5153-9244-4ADA-9AFA-61B58AD239BD

P407

Q43873032-409B0D4F-82A8-40A4-BF23-43486B808C6F

P433

Q43873032-57D781BB-6D51-4BCE-AC9E-F6486A22907A

P478

Q43873032-0866F3C5-F5CF-459D-94CC-C874DA496465

P577

Q43873032-6731B75A-FFCD-46FA-8246-123C1D386000

P5875

Q43873032-7EDAA4DF-563C-4FFF-ACC0-EBBCA238A1A6

P6179

Q43873032-46D55ED6-AC71-43F1-A66B-9E7F7DD2CD8F

P698

Q43873032-F6384723-EAD7-49A7-947F-65A44192A9E0

P356

P1433

Nature Medicine

P1476

Rapamycin inhibits primary and ...... lar endothelial growth factor.

@en

P2093

Carl Zuelke

http://www.w3.org/2001/XMLSchema#string

Christiane J Bruns

http://www.w3.org/2001/XMLSchema#string

Edward K Geissler

http://www.w3.org/2001/XMLSchema#string

Gudrun Koehl

http://www.w3.org/2001/XMLSchema#string

Karl-Walter Jauch

http://www.w3.org/2001/XMLSchema#string

Markus Guba

http://www.w3.org/2001/XMLSchema#string

Markus Steinbauer

http://www.w3.org/2001/XMLSchema#string

Matthias Anthuber

http://www.w3.org/2001/XMLSchema#string

Matthias Hornung

http://www.w3.org/2001/XMLSchema#string

Philipp von Breitenbuch

http://www.w3.org/2001/XMLSchema#string

P2888

P304

128-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM0202-128

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11538042

http://www.w3.org/2001/XMLSchema#string

P6179

1015189512

http://www.w3.org/2001/XMLSchema#string

P698

11821896

http://www.w3.org/2001/XMLSchema#string